Predictors of Adherence to Orencia
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT01136707
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to examine the relationship between loading dose and adherence to Orencia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 422
Inclusion Criteria
- Patients will be identified based on the presence of first infusion claim during study period for Orencia
- At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date
- Patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below
- Patients with a minimum of 3 infusion claims for Orencia
- Only those patients will be included whose first 3 infusion claims occur within 84 days
Read More
Exclusion Criteria
- Patients less than 18 years of age at index date.
- One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period
- Patients who switch between biologics within their first three infusion claims
- Restarts, defined as those patients who go back on Orencia after a gap of 42 days
- Patients who are on other biologics at the same time as Orencia
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total number of days on Orencia therapy 6 months
- Secondary Outcome Measures
Name Time Method Rheumatoid arthritis-related and total healthcare costs 6 months